Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

China flag China · Delayed Price · Currency is CNY
20.35
-0.03 (-0.15%)
At close: Jan 23, 2026
3.40%
Market Cap3.39B
Revenue (ttm)596.47M
Net Income (ttm)169.67M
Shares Out166.80M
EPS (ttm)1.01
PE Ratio20.15
Forward PE18.93
Dividend0.20 (0.99%)
Ex-Dividend DateJul 10, 2025
Volume3,822,923
Average Volume4,632,097
Open20.39
Previous Close20.38
Day's Range20.24 - 20.45
52-Week Range19.05 - 31.13
Beta0.67
RSI32.23
Earnings DateApr 23, 2026

About Cabio Biotech (Wuhan)

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 565
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688089
Full Company Profile

Financial Performance

In 2024, Cabio Biotech (Wuhan)'s revenue was 555.59 million, an increase of 25.19% compared to the previous year's 443.80 million. Earnings were 124.21 million, an increase of 35.94%.

Financial Statements